FMC sees full-year 2026 revenue excluding India at $3.50 bln to $3.70 bln
Company lowers full-year adjusted EBITDA to $620 mln to $680 mln
FMC expects a return to year-over-year growth in Q4 2026
Overview
U.S. agricultural sciences firm's Q2 revenue fell 17% and missed analyst expectations
Adjusted EPS and adjusted EBITDA for Q2 both beat analyst estimates
Company cites lower volumes and pricing pressures, especially in North America, for revenue decline
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$867 mln
$905.17 mln (11 Analysts)
Q2 Adjusted EPS
Beat
$0.26
$0.22 (14 Analysts)
Q2 Net Loss
$187 mln
Q2 Adjusted EBITDA
Beat
$153 mln
$146.20 mln (12 Analysts)
Result Drivers
Volume and pricing pressure - Co said Q2 revenue fell due to lower diamide partner orders, reduced demand for core legacy products in North America, and price declines driven by pressure on legacy products and planned pricing actions for Rynaxypyr
Growth portfolio - Co said growth portfolio grew mid-single digits as strong performances from new active ingredients and Cyazypyr offset lower Plant Health sales
Cost actions and FX - Co said lower price and volume were partially offset by favorable costs and a moderate FX tailwind
FMC•
